pharma · Acne Rosacea · Atopic Dermatitis · DRMA
Dermata Therapeutics
Dermata Therapeutics patent portfolio — 30 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2014
- Employees
- 12
- Programs
- 4
- Drugs
- 2
- Patents
- 30
Dermata Therapeutics patents
30 pharmaceutical patents indexed for Dermata Therapeutics. 0 expire within 24 months.
Dermata Therapeutics has 30 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12208123
Compositions and methods for the treatment of skin conditions
granted -
US 6759396
Compositions based on a synergistic mixture of at least one VDR ligand and a retinoid
expired -
US 6593359
Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis
expired -
US 6515021
Bicyclic aromatic compounds
expired -
US 6506796
Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis
expired -
US 6368608
Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6326510
Bi-aromatic compounds, compositions containing them and uses
expired -
US 6313162
Propynyl or dienyl biaromatic compounds
expired -
US 6297290
Composition containing a nerve fiber reactivity modulating compound
expired -
US 6287549
Method for removing superfluous hairs
expired -
US 6258775
Bi-aromatic compounds, pharmaceutical and cosmetic compositions containing same and uses
expired -
US 6248791
Stimulating the differentiation of preadipocytic cells and therapies based thereon
expired -
US 6248749
Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation
expired -
US 6225328
Adamantyl-substituted retinoids and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6211239
Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
expired -
US 6194450
Polyaromatic heterocyclic compounds and pharmaceutical compositions comprised thereof
expired -
US 6171603
Bioaromatic amido compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6162445
Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6162815
RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof
expired -
US 6156750
Bioactive bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6156788
Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6150413
Triaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6147255
Bicyclic-aromatic compounds
expired -
US 6106848
Topically applicable O/W emulsions having high glycol content and at least one biologically active agent
expired -
US 6074653
Cosmetic/dermatological w/o emulsions highly concentrated in hydroxy acids
expired -
US 6057341
Bi-aromatic dibenzofuran derivatives and their use in human and veterinary medicine and in cosmetics
expired -
US 6051243
Polyaromatic amide compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6046220
Propynyl or dienyl biaromatic compounds
expired -
US 6030952
Benzofuran-acrylic acid derivatives and their use as modulators of RXRs or RARs receptors
expired -
US 6015569
Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
expired
Frequently asked questions
How many patents does Dermata Therapeutics have?
30 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Dermata Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.